
97
B&S Group S.A.
Annual Report 2022
of SHV Holdings) and as member of the Executive Board of Directors of SHV
Holdings. As such, Derk Doijer has a solid understanding of B&S’ business
environment. In addition, his background in governance, compliance and risk
management will bring substantial added value to the Supervisory Board.
Bert Tjeenk Willink has significant Supervisory Board membership experience
gained in the pharmaceutical and biotech industry and multiple start-ups in
different sectors. He gained 30 years of experience in the pharmaceutical industry,
for instance, with multinational Boehringer Ingelheim GmbH as Member of the
Board of Managing Directors. With his extensive experience in multiple managerial
roles within large international organisations and his broad strategic and operational
experience in marketing & sales and business development, he will bring substantial
added value to the Supervisory Board.
Board conflicts of interest
Conflicts of interest should be handled in accordance with Art. 28 of the Articles of
Association. If a member of the Executive Board or the Supervisory Board has a
direct or indirect financial interest opposite to the interest of the Company in any
transaction that requires approval from the Executive Board or the Supervisory
Board, he or she should inform the Boards as per Art. 28.1 of the Articles of
Association. The member may not take part in the deliberations relating to the
transaction and may not vote on transaction related resolutions. For details on these
transactions, reference is made to note 33 of the financial statements in this report.
These transactions were compliant with arm’s length principles. The following
transactions were reported:
ը
During the EGM on December 15, 2022 conflicts of interest were declared in
connection with the confidential non-binding indicative offer received from its
shareholder Sarabel on July 6, 2022.
ը
The following Supervisory Board members who have consequently abstained
from deliberations and vote in respect of the offer:
ը
Mr. Willem Blijdorp, who has declared an interest in the potential transaction
contemplated by the Offer by virtue of his position as a director of Sarabel
and his controlling interest in Sarabel.
ը
Mr. Leendert Blijdorp, who has declared an interest in the potential
transaction contemplated by the Offer by virtue of having a relative by blood
in the first degree that is a member of the management board or supervisory
board – or is a representative in some other way – of a legal entity which
holds at least ten percent of the shares in B&S.
The independent members of the Supervisory Board, together with the designated
Executive Board members, reviewed and assessed the offer in consultation with
legal and financial advisors, in accordance with their responsibilities and fiduciary
duties and taking into account the interests of the Company and all its stakeholders,
and rejected the offer on July 19, 2022. Sarabel has withdrawn the offer in its letter
dated August 31, 2022. Mr. Bas Schreuders, Executive Board member, has also
declared an interest (taking a prudent approach and despite such interest not being
personal nor financial) in the potential transaction contemplated by the offer by
virtue of his capacity as a director of Sarabel and has therefore abstained from
deliberations and vote within the Executive Board in respect of the Offer. It was
further noted on behalf of the Executive Board that the designated Executive Board
members, together with the independent members of the Supervisory Board,
reviewed and assessed the offer in consultation with legal and financial advisors in
accordance with their responsibilities and fiduciary duties and taking into account
the interests of B&S and all its stakeholders, and rejected the offer.
In addition to the transactions described above, other transactions that entail a
potential conflict of interest have been identified, following the review of the
Company’s governance practices and policies. This review was initiated as financial
relations of B&S management and majority shareholder Sarabel Invest S.à. r.l.,
the investment vehicle of Willem Blijdorp, surfaced during 2022 that previously had
not been disclosed. Such relations could indicate a (potential) conflict of interest,
Introduction About B&S Results Financial statementsGovernance